McClellan’s “Smart Regulation”: More Early Testing And Phase IV Studies
Increased emphasis on early stage testing and Phase IV studies could result in lower drug development costs, FDA Commissioner Mark McClellan said Dec. 11
Increased emphasis on early stage testing and Phase IV studies could result in lower drug development costs, FDA Commissioner Mark McClellan said Dec. 11